載入中
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
一般交易時段
US$40.00
−US$0.84 · -2.06%
盤中時間採用ET。市場資料可能有所延遲。
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
日內區間
目前US$40.00
52週區間
目前US$40.00
盤中時間採用ET。市場資料可能有所延遲。
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
日內區間
目前US$40.00
52週區間
目前US$40.00
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 26.3萬 USD | — | — | — | — |
| 毛利 | −26.3萬 USD | — | — | — | — |
| 研究與開發 | 8585.6萬 USD | 8077.8萬 USD | 6457.4萬 USD | 3102.2萬 USD | 2047.4萬 USD |
| 銷售、一般及管理費用 | 3380.2萬 USD | 2377.6萬 USD | 1895.5萬 USD | 776.9萬 USD | 428.8萬 USD |
| 營業費用 | 1.19億 USD | 1.05億 USD | 8352.9萬 USD | 3879.1萬 USD | 2476.2萬 USD |
| 利息收入 | 1601.3萬 USD | 1489.1萬 USD | 1196.7萬 USD | 112.9萬 USD | 2.2萬 USD |
| 折舊和攤銷 | 26.3萬 USD | 31.7萬 USD | 29.7萬 USD | 21.5萬 USD | 11.5萬 USD |
| 營業利益 | −1.2億 USD | −1.05億 USD | −8352.9萬 USD | −3879.1萬 USD | −2476.2萬 USD |
| 淨利 | −1.04億 USD | −8902.4萬 USD | −7158.4萬 USD | −3766.2萬 USD | −2474萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$75.14
上漲空間 87.85%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年2月24日 | 1:4 | — | — |
已生效 2023年2月24日
1:4
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM6100.17萬0.08%787.4億 USD0.19%US$276.43-0.53%
iShares Russell 2000 Growth ETFIWO2195.71萬0.16%139.17億 USD0.24%US$351.36-0.67%
iShares Biotechnology ETFIBB1930.7萬0.18%108.2億 USD0.44%US$201.06-1.57%
Dimensional - US Small Cap ETFDFAS1447萬0.04%338.04億 USD0.31%US$78.03-0.18%
Vanguard Russell 2000 ETFVTWO1425.52萬0.08%180億 USD0.06%US$111.63-0.57%
Schwab U.S. Small-Cap ETFSCHA1371.52萬0.06%217.13億 USD0.03%US$32.505-0.47%
iShares U.S. Pharmaceuticals ETFIHE903.25萬0.58%15.52億 USD0.37%US$97.54-2.64%
Vanguard Health Care ETFVHT852萬0.04%220億 USD0.09%US$316.51-1.30%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
